Zofin is under clinical development by ZEO ScientifiX and currently in Phase II for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID). According to GlobalData, Phase II drugs for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Zofin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zofin overview
Zofin under development for the treatment of severe acute respiratory syndrome (SARS) caused by the influenza infection, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), post-acute sequelae of covid 2019 (PASC or long covid), heart failure with preserved ejection fraction and knee osteoarthritis. The therapeutic candidate comprises of amniotic fluid-derived chemokines, cytokines growth factors, extracellular vesicles and hyaluronic acid.
It was also underdevelopment for the treatment of chronic obstructive pulmonary disease (COPD).
ZEO ScientifiX overview
ZEO ScientifiX, formerly Organicell Regenerative Medicine Inc, involves in the supply of regenerative anti-aging medicine (RAAM) related products and services. It focuses on marketing placental tissue with amnion membranes and fluid used in the management of orthopedic conditions and pain. The company offers RAAM-related products developed by third parties under exclusive supply arrangements with outside manufacturers and/or from products developed from internally based research and development activities. It also distributes RAAM Products and markets RAAM-related services through a referral network of doctors and clinics. ZEO ScientifiX is headquartered in Miami, Florida, the US.
For a complete picture of Zofin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
